TY - JOUR
T1 - Congestive heart failure
T2 - Pharmacological agents and the potential of B-type natriuretic peptide
AU - James, Kenneth D.
AU - Cataliotti, Alessandro
AU - Schirger, John A.
AU - Plonka, Shannon
AU - Burnett, John C.
PY - 2005
Y1 - 2005
N2 - Congestive heart failure (CHF) is a life-threatening cardiovascular disease that is increasing in prevalence. It is a common cause of death and is accompanied by high direct and indirect costs for treatment. The current situation faced by patients and the medical community with regard to this ailment is one of high mortality, repeated hospitalizations, and combination therapies. The various classes of pharmacological agents that are currently used for patients suffering from CHF include angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), aldosterone antagonists, beta-blockers, calcium channel blockers (CCBs), digitalis drugs, diuretics, inotropic agents, nitrates, and vasodilators. While these agents are all important therapeutic tools in the treatment of CHF, the prognosis for patients with CHF remains poor. Thus improvement of the current pharmacological armamentarium is greatly needed. An endogenous peptide, B-type natriuretic peptide (BNP), has been increasingly utilized in the setting of acute CHF since its approval in 2001. This peptide, or a derivative thereof, has great potential for the treatment of patients at various stages in the progression of heart failure This review provides an overview of current pharmacological strategies in CHF and addresses potential future developments in the use of BNP for the treatment of CHF.
AB - Congestive heart failure (CHF) is a life-threatening cardiovascular disease that is increasing in prevalence. It is a common cause of death and is accompanied by high direct and indirect costs for treatment. The current situation faced by patients and the medical community with regard to this ailment is one of high mortality, repeated hospitalizations, and combination therapies. The various classes of pharmacological agents that are currently used for patients suffering from CHF include angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), aldosterone antagonists, beta-blockers, calcium channel blockers (CCBs), digitalis drugs, diuretics, inotropic agents, nitrates, and vasodilators. While these agents are all important therapeutic tools in the treatment of CHF, the prognosis for patients with CHF remains poor. Thus improvement of the current pharmacological armamentarium is greatly needed. An endogenous peptide, B-type natriuretic peptide (BNP), has been increasingly utilized in the setting of acute CHF since its approval in 2001. This peptide, or a derivative thereof, has great potential for the treatment of patients at various stages in the progression of heart failure This review provides an overview of current pharmacological strategies in CHF and addresses potential future developments in the use of BNP for the treatment of CHF.
KW - BNP
KW - Congestive heart failure
KW - Natriuretic peptide
KW - Nesiritide
UR - http://www.scopus.com/inward/record.url?scp=21044458028&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=21044458028&partnerID=8YFLogxK
U2 - 10.2174/0929867054020909
DO - 10.2174/0929867054020909
M3 - Review article
C2 - 15974994
AN - SCOPUS:21044458028
SN - 0929-8673
VL - 12
SP - 1439
EP - 1447
JO - Current Medicinal Chemistry
JF - Current Medicinal Chemistry
IS - 12
ER -